• Pfizer soared 13% in pre-market trading on Monday after announcing its coronavirus vaccine succeeded in final stage clinical trials.
  • The US drugmaker's vaccine is in development with German biotech firm BioNTech, whose shares soared 26%.
  • The vaccine won't be immediately available as it still needs to be reviewed by the US Food and Drug Administration.
  • Visit Business Insider's homepage for more stories.

Pfizer leapt 13% in pre-market trading on Monday after the drugmaker announced that its experimental Covid-19 vaccine succeeded in late-stage trials.

The US pharma firm said its vaccine, developed with German biotech partner BioNTech, is over 90% effective in preventing Covid-19 infection.

BioNTech's shares soared 26%.

More to follow

Read the original article on Business Insider

Receive a daily news update on your cellphone. Or get the best of our site emailed to you.

Go to the Business Insider front page for more stories.